Business Context and Reporting Period
Jazz Pharmaceuticals Plc (the "Company") filed a Form 8-K on October 1, 2015, reporting a material definitive agreement entered into by its subsidiary, Jazz Pharmaceuticals Ireland Limited ("Jazz Ireland").
Key Financial Metrics
This filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a new contractual agreement.
Material Changes and Agreement Details
On October 1, 2015, Jazz Ireland entered into a Master Manufacturing Services Agreement with Patheon Pharmaceuticals Inc. ("Patheon"). Key terms include:
- Scope: Patheon will provide manufacturing services for drug products specified by Jazz, including Xyrem (sodium oxybate) oral solution.
- Term: The agreement expires on December 31, 2020, with automatic renewal for successive two-year terms if services are ongoing, unless 18 months' prior notice of termination is given.
- Termination Rights: Jazz Ireland may terminate for any reason with 12 months' prior written notice. Both parties retain early termination rights for uncured material breaches.
- Superseding Agreement: This Master Agreement replaces the Xyrem Manufacturing Services and Supply Agreement dated March 13, 2007.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of general risks. The primary contingency noted is the reliance on Patheon for manufacturing services under the new terms, with the full agreement to be filed as an exhibit to the Company's 2015 Form 10-K.
Investor Verification Checklist
- Verify the full text of the Master Manufacturing Services Agreement when filed as an exhibit to the 2015 Form 10-K.
- Confirm the specific products and volume commitments included under the new agreement beyond Xyrem.
- Assess the impact of the 12-month termination notice period on supply chain continuity.
- Review the transition plan from the 2007 agreement to the 2015 Master Agreement.